Vanda's Atypical Approval: Is It Time to Rethink Attitudes Toward FDA?
This article was originally published in RPM Report
Executive Summary
The atypical antipsychotic iloperidone took a treacherous route to market. What does FDA’s decision-making from not approvable to approval in 10 months say about approval standards?